See more : PACCAR Inc (PCAR) Income Statement Analysis – Financial Results
Complete financial analysis of Barings Corporate Investors (MCI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Barings Corporate Investors, a leading company in the Asset Management industry within the Financial Services sector.
- Castile Resources Limited (CLRSF) Income Statement Analysis – Financial Results
- Heartland Media Acquisition Corp. (HMA-WT) Income Statement Analysis – Financial Results
- Vector Acquisition Corporation II (VAQC) Income Statement Analysis – Financial Results
- Alpcot Holding AB (publ) (ALPCOT-B.ST) Income Statement Analysis – Financial Results
- QUEST CAPITAL MARKETS LIMITED (QUESTCAP.BO) Income Statement Analysis – Financial Results
Barings Corporate Investors (MCI)
Industry: Asset Management
Sector: Financial Services
Website: https://www.babsoncapital.com/Strategies/Trusts/MCI/Default.aspx
About Barings Corporate Investors
Babson Capital Corporate Investors trust is a closed ended fixed income mutual fund launched and managed by Barings LLC. It invests in fixed income markets of the United States. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in a portfolio of privately placed, below-investment grade, long term corporate debt obligations. The fund also invests in marketable investment grade debt securities, other marketable debt securities, and marketable common stocks. It was formerly known as Babson Capital Corporate Investors. Babson Capital Corporate Investors trust was formed in 1971 and is domiciled in the United States.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 41.19M | 16.21M | 54.45M | 16.22M | 39.95M | 10.99M | 44.54M | 28.18M | 26.80M | 30.20M | 28.88M | 30.25M |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 41.19M | 16.21M | 54.45M | 16.22M | 39.95M | 10.99M | 44.54M | 28.18M | 26.80M | 30.20M | 28.88M | 30.25M |
Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 1.34M | 1.18M | 1.05M | 889.01K | 937.22K | 1.40M | 964.49K | 4.43M | 4.79M | 4.63M | 4.43M | 4.16M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 1.34M | 1.18M | 1.05M | 889.01K | 937.22K | 1.40M | 964.49K | 4.43M | 4.79M | 4.63M | 4.43M | 4.16M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 1.34M | 1.18M | 1.05M | 889.01K | 937.22K | 1.40M | 964.49K | 641.25K | 7.93M | 4.14M | 4.88M | 11.15M |
Cost & Expenses | 5.62M | 1.18M | 1.05M | 889.01K | 937.22K | 1.40M | 964.49K | 641.25K | 7.93M | 4.14M | 4.88M | 11.15M |
Interest Income | 40.63M | 28.08M | 24.33M | 28.70M | 27.60M | 29.45M | 27.96M | 1.58M | 1.58M | 1.58M | 1.58M | 1.58M |
Interest Expense | 2.08M | 1.71M | 1.07M | 1.06M | 1.06M | 1.06M | 1.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | -46.47K | -23.32M | -20.54M | -25.45M | -23.64M | -25.27M | -26.77M | -23.76M | -22.01M | -25.57M | -24.45M | -26.09M |
EBITDA | 0.00 | 0.00 | 67.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.73M |
EBITDA Ratio | 0.00% | 103.28% | 98.07% | 94.52% | 97.65% | 96.88% | 101.24% | 12.36% | -17.63% | 23.80% | 26.74% | 45.38% |
Operating Income | 35.57M | 16.74M | 53.39M | 15.33M | 39.01M | 10.65M | 45.10M | 23.76M | 22.01M | 25.57M | 24.45M | 26.09M |
Operating Income Ratio | 86.36% | 103.28% | 98.07% | 94.52% | 97.65% | 96.88% | 101.24% | 84.29% | 82.13% | 84.68% | 84.68% | 86.25% |
Total Other Income/Expenses | 2.09M | -7.91M | 406.60K | -10.11M | 15.37M | -15.68M | 16.81M | 3.48M | -4.72M | 7.19M | 7.72M | 13.73M |
Income Before Tax | 37.67M | 15.03M | 53.39M | 15.33M | 39.01M | 9.59M | 43.58M | 27.24M | 17.28M | 32.76M | 32.18M | 39.82M |
Income Before Tax Ratio | 91.45% | 92.72% | 98.07% | 94.52% | 97.65% | 87.24% | 97.83% | 96.65% | 64.49% | 108.48% | 111.41% | 131.63% |
Income Tax Expense | 706.22K | 766.22K | 585.25K | 15.33M | 39.01M | -161.14K | 26.77M | 3.48M | -4.72M | 7.19M | 7.72M | 2.12M |
Net Income | 36.96M | 14.26M | 52.81M | 15.33M | 39.01M | 9.59M | 43.58M | 27.24M | 17.28M | 32.76M | 32.18M | 37.70M |
Net Income Ratio | 89.73% | 88.00% | 96.99% | 94.52% | 97.65% | 87.24% | 97.83% | 96.65% | 64.49% | 108.48% | 111.41% | 124.63% |
EPS | 1.82 | 0.71 | 2.60 | 0.76 | 1.93 | 0.48 | 2.19 | 1.38 | 0.88 | 1.68 | 1.66 | 1.96 |
EPS Diluted | 1.82 | 0.71 | 2.60 | 0.76 | 1.93 | 0.48 | 2.19 | 1.38 | 0.88 | 1.68 | 1.66 | 1.96 |
Weighted Avg Shares Out | 20.26M | 20.09M | 20.26M | 20.18M | 20.21M | 19.97M | 19.90M | 19.79M | 19.66M | 19.53M | 19.39M | 19.24M |
Weighted Avg Shares Out (Dil) | 20.26M | 20.09M | 20.31M | 20.18M | 20.21M | 19.97M | 19.90M | 19.79M | 19.66M | 19.53M | 19.39M | 19.24M |
Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD DATA IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Closed-End Funds: Misclassifications Can Lead To Misunderstanding
5 Best CEFs To Buy This Month (February 2023)
5 Best CEFs To Buy This Month (January 2023)
The 8% Income Portfolio: 2022 Year-End Review
MCI: Superb Long-Term Returns But Challenging Macro
5 Best CEFs To Buy This Month (December 2022)
5 Best CEFs To Buy This Month (November 2022)
CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease
Source: https://incomestatements.info
Category: Stock Reports